Company intelligence / Profile preview
CommBio Therapeutics
Shanghai, Shanghai Shi, Chinasec.gov ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
CommBio Therapeutics develops a new class of medicines using bacterial vector gene therapy. Their lead clinical candidate CBT102-A targets phenylketonuria (PKU) and has reached Phase I clinical trials. Other pipeline assets target autoimmune and inflammatory diseases such as systemic lupus erythematosus, inflammatory bowel disease, and rheumatoid arthritis. The company leverages proprietary technology platforms to engineer bacteria that deliver therapeutic payloads in the gut or systemically. Early results have led to recognition as a top growth biotech in China.[1][2][3][4]
- Therapeutic areas
- Metabolic DisordersOncologyImmunologyRheumatologyGastroenterology
- Modalities
- Bacterial vector gene therapy (engineered bacteria expressing therapeutic proteins)[1][4]Recombinant LBP (likely refers to recombinant live biotherapeutic products)[3]
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Collaborates with academic scientists, clinicians, biotechnology and pharmaceutical companies; specific partners not named.[4]
Beyond the preview
Go deeper on CommBio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CommBio Therapeutics.